 In a report released today,Jay Olsonfrom Oppenheimer maintained aBuyrating on Millendo Therapeutics MLNDResearch Report. The companys shares closed last Monday at 6.10, close to its 52-week low of 4.56.According toTipRanks.com, Olson 